Lisata Therapeutics, Inc. revenue
Lisata Therapeutics, Inc.'s revenue was $170,000 in fiscal 2025, down 83.0% on the year before. Since fiscal 2010 ($69.8m) it has grown at a compound -45.2% a year. Over the last twelve months it was $100,000.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70 | 10 | 14 | 15 | 18 | 22 | 35 | 0 | 0 | 1 | 0 | 0 |
| Growth on the year before | — | −85.6% | +42.6% | +2.4% | +22.3% | +25.4% | +56.9% | −100.0% | — | — | −83.0% | — |
| Gross profit | 20 | 1 | 2 | 2 | 2 | 2 | 4 | — | — | — | — | — |
| Gross margin | 28.9% | 14.0% | 16.6% | 11.7% | 12.6% | 10.4% | 11.8% | — | — | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Lisata Therapeutics, Inc. | $100,000 | -90.7% | — |
| Ibio, Inc. | $100,000 | -75.0% | -62.4% |
| AIM Immunotech Inc. | $95,000 | -21.5% | -17.3% |
| Celldex Therapeutics, Inc. | $158,000 | -97.3% | -63.5% |
| Clene Inc. | $197,000 | -31.1% | -36.9% |
| Cervomed Inc. | $331,295 | -95.7% | -52.7% |
Compare with peers
- Ibio, Inc. revenue
- AIM Immunotech Inc. revenue
- Celldex Therapeutics, Inc. revenue
- Clene Inc. revenue
- Cervomed Inc. revenue
Head to head: IBIO vs LSTAAIM vs LSTACLDX vs LSTA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies